Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dabomb Protein Biotech's Total Assets for the quarter that ended in Dec. 2025 was NT$1,095.8 Mil.
During the past 12 months, Dabomb Protein Biotech's average Total Assets Growth Rate was -7.40% per year.
During the past 3 years, the average Total Assets Growth Rate was -3.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 2.60% per year.
During the past 10 years, the average Total Assets Growth Rate was 13.90% per year.
During the past 13 years, Dabomb Protein Biotech's highest 3-Year average Total Assets Growth Rate was 38.00%. The lowest was -3.70%. And the median was 15.00%.
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Dabomb Protein Biotech's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Dabomb Protein Biotech Total Assets Related Terms
Dabomb Protein Biotech Total Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Dabomb Protein Biotech's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dabomb Protein Biotech (ROCO:6578) has a Total Assets of NT$1,095.8 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Dabomb Protein Biotech and its competitors.
Is Dabomb Protein Biotech's Total Assets too high?
Dabomb Protein Biotech's current Total Assets is NT$1,095.8 Mil. Overall, Dabomb Protein Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dabomb Protein Biotech's Total Assets compare to KHC and GIS?
Dabomb Protein Biotech's Total Assets of NT$1,095.8 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Consumer Packaged Goods company?
A good Total Assets depends on the Consumer Packaged Goods industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Dabomb Protein Biotech and its competitors. Dabomb Protein Biotech's current Total Assets is NT$1,095.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dabomb Protein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Dabomb Protein Biotech (ROCO:6578) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$14.48, compared to a current price of NT$16.35 — trading 12.9% above its estimated fair value. The current Total Assets is NT$1,095.8 Mil. Dabomb Protein Biotech's overall GF Score™ is 58/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Dabomb Protein Biotech (ROCO:6578), the current Total Assets is NT$1,095.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dabomb Protein Biotech (ROCO:6578) Overvalued in 2026?
Based on GuruFocus' analysis, Dabomb Protein Biotech stock appears to be overvalued.
The current stock price of NT$16.35 is trading 12.9% above its estimated GF Value™ of NT$14.48.
GuruFocus considers Dabomb Protein Biotech to be Modestly Overvalued.
Key valuation signals for ROCO:6578:
Total Assets: NT$1,095.8 Mil
GF Value™: NT$14.48 vs. price of NT$16.35 (12.9% above fair value)
No single metric tells the full story. See the ROCO:6578 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dabomb Protein Biotech Corp is engaged in the manufacture, wholesale, and sale of hydrolyzed soy protein. The products of the company include Plant protein, Antibiotics alternatives, Pet care, Core technology, and CDMO(ODM/OEM). The company operates in a single segment engaged in the manufacture, wholesale and sales of hydrolysed soy protein. Geographically it operates in Malaysia, Taiwan, USA, Vietnam, and Others with majority of the revenue deriving from Vietnam.
58GF Score
Get the complete analysis for ROCO:6578
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6578 has been successfully added to your 
